Impact of Case-management on Therapeutic Alliance With First Episode Psychosis Patients (CAMAT)

2016-08-23 12:23:22 | BioPortfolio


The first aim of this study is to test the effect of the case management on the evolution of therapeutic alliance in patients with first episode psychosis in comparison with traditional nursing. The second aim is to test the effect of case management on nurses' well-being in comparison with traditional nursing. The third objective aims to show if therapeutic alliance is associated with insight in patients and with clinical and demographic data.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Psychotic Disorders




Not yet recruiting


University Hospital, Caen

Results (where available)

View Results


Published on BioPortfolio: 2016-08-23T12:23:22-0400

Clinical Trials [868 Associated Clinical Trials listed on BioPortfolio]

Stage-specific Case Management for Early Psychosis

One of the commonly adopted strategies in improving outcome in psychotic disorders is by focused, specific and intensive intervention in the initial few years of the disorder. However the ...

Quetiapine in the Treatment of Psychotic Depression - a Pilot Study

Atypical antipsychotics have been found not only to be beneficial in the treatment of psychotic disorders, but even for depressive symptoms in patients with schizophrenia. Remarkably, prel...

Treatment of MDEs During the Course of Psychotic Disorders With Duloxetine

We evaluate the efficacy and tolerability of duloxetine in the treatment of major depressive episodes during the course of psychotic disorders

Screening for Childhood-Onset Psychotic Disorders

The purpose of this study is to screen and evaluate children with psychotic disorders to establish or confirm their diagnosis and to collect data about their condition. This study will als...

Tracking Service Use and Outcomes II:First Episode Psychosis and Psychotic Disorders Clinic

Main Research questions: 1. Who are the patients referred for treatment at the Psychotic Disorders Clinic? 2. What are the outcomes from treatment for first episode psychosis in mult...

PubMed Articles [19309 Associated PubMed Articles listed on BioPortfolio]

Use of psychotropic medication in women with psychotic disorders at menopause and beyond.

Drugs have been extensively prescribed for the treatment of psychotic symptoms in schizophrenia and related disorders, as well as for the management of psychotic features in delirium, dementia and aff...

Temperaments in psychotic and major affective disorders.

Assessment of affective temperaments with the extensively validated, 110-item TEMPS-A autoquestionnaire has been used to characterize patients with mood disorders, and its scores have been associated ...

Treatment against the patient's will exemplified by electroconvulsive therapy : Clinical, legal and ethical aspects.

Severe affective and psychotic disorders may be accompanied by legal incapacity. If in this case the patient refuses treatment and in parallel there is a risk of serious damage to health, treatment c...

Clinical features of psychotic and non-psychotic bipolar patients.

Psychotic symptoms are common in the case of manic, depressive and mixed episodes of bipolar disorder; however, the assessment of delusions and hallucinations is frequently improper, thus the patients...

Combined NMDA Inhibitor Use in a Patient With Multisubstance-induced Psychotic Disorder.

: Novel psychoactive substance use is a major social concern. Their use may elicit or uncover unpredictably as yet undescribed clinical pictures. We aimed to illustrate a multisubstance use case indis...

Medical and Biotech [MESH] Definitions

Disorders in which the essential feature is a severe disturbance in mood (depression, anxiety, elation, and excitement) accompanied by psychotic symptoms such as delusions, hallucinations, gross impairment in reality testing, etc.

Management control systems for structuring health care delivery strategies around case types, as in DRGs, or specific clinical services.

Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)

A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)

Marked disorders of thought (delusions, hallucinations, or other thought disorder accompanied by disordered affect or behavior), and deterioration from a previous level of functioning.

More From BioPortfolio on "Impact of Case-management on Therapeutic Alliance With First Episode Psychosis Patients (CAMAT)"

Quick Search


Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.

Searches Linking to this Trial